The abstract is read at the publisher; the summary is JClub's.
Dose-escalated focal salvage high-dose-rate brachytherapy for intraprostatic radiorecurrence showed no acute grade ≥3 genitourinary or GI toxicity and 3-year MFS of 85.9%.
- Why it matters: Evidence is limited for managing intraprostatic radiorecurrence after prior definitive radiotherapy and for whether genomic classifiers can identify patients who might benefit from treatment intensification.
- What they did: In the multi-institutional F-SHARP phase I/II trial, 62 men received up to 30 Gy in 1–2 fractions, with toxicity and time-to-event outcomes including bPFS, rPFS, LRFS, and MFS; genomic classifier scores were measured in 31 patients.
- The result: Median follow-up was 39.4 months, with two late grade 3 toxicities (3.2%) and no QoL changes meeting minimal clinically important difference; higher genomic classifier scores predicted worse bPFS, rPFS, LRFS, and MFS, and all patients with GC score >0.85 (n=4) had biochemical, local, and metastatic recurrence.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.